These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38821468)

  • 1. Repurposing drugs for the treatment of osteoarthritis.
    Kuswanto W; Baker MC
    Osteoarthritis Cartilage; 2024 Aug; 32(8):886-895. PubMed ID: 38821468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of disease-modifying anti-rheumatic drugs in osteoarthritis: A meta-analysis.
    Mathieu S; Tournadre A; Soubrier M; Sellam J
    Joint Bone Spine; 2022 Nov; 89(6):105444. PubMed ID: 35908643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current Treatment Options for Osteoarthritis.
    Hermann W; Lambova S; Muller-Ladner U
    Curr Rheumatol Rev; 2018; 14(2):108-116. PubMed ID: 28875826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands (OA TREAT): study protocol for a randomized controlled trial.
    Detert J; Klaus P; Listing J; Höhne-Zimmer V; Braun T; Wassenberg S; Rau R; Buttgereit F; Burmester GR
    Trials; 2014 Oct; 15():412. PubMed ID: 25348033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease-modifying drugs in osteoarthritis: current understanding and future therapeutics.
    Oo WM; Yu SP; Daniel MS; Hunter DJ
    Expert Opin Emerg Drugs; 2018 Dec; 23(4):331-347. PubMed ID: 30415584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of key regulators responsible for dysregulated networks in osteoarthritis by large-scale expression analysis.
    Shi S; Wan F; Zhou Z; Tao R; Lu Y; Zhou M; Liu F; Liu Y
    J Orthop Surg Res; 2021 Apr; 16(1):259. PubMed ID: 33853636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systems to assess the progression of finger joint osteoarthritis and the effects of disease modifying osteoarthritis drugs.
    Verbruggen G; Goemaere S; Veys EM
    Clin Rheumatol; 2002 Jun; 21(3):231-43. PubMed ID: 12111630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repurposed Drugs as Potential Therapeutic Candidates for the Management of Alzheimer's Disease.
    Shoaib M; Kamal MA; Rizvi SMD
    Curr Drug Metab; 2017; 18(9):842-852. PubMed ID: 28595531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical review of chondroitin sulfate in osteoarthritis.
    Uebelhart D
    Osteoarthritis Cartilage; 2008; 16 Suppl 3():S19-21. PubMed ID: 18674931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. OARSI-OMERACT initiative: defining thresholds for symptomatic severity and structural changes in disease modifying osteoarthritis drug (DMOAD) clinical trials.
    Manno RL; Bingham CO; Paternotte S; Gossec L; Halhol H; Giacovelli G; Rovati L; Mazzuca SA; Clegg DO; Shi H; Tajana Messi E; Lanzarotti A; Dougados M
    Osteoarthritis Cartilage; 2012 Feb; 20(2):93-101. PubMed ID: 22178465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydroxychloroquine in the treatment of erosive osteoarthritis.
    Bryant LR; des Rosier KF; Carpenter MT
    J Rheumatol; 1995 Aug; 22(8):1527-31. PubMed ID: 7473478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospects of Disease-Modifying Osteoarthritis Drugs.
    Oo WM
    Rheum Dis Clin North Am; 2024 Aug; 50(3):483-518. PubMed ID: 38942581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis.
    Abadie E; Ethgen D; Avouac B; Bouvenot G; Branco J; Bruyere O; Calvo G; Devogelaer JP; Dreiser RL; Herrero-Beaumont G; Kahan A; Kreutz G; Laslop A; Lemmel EM; Nuki G; Van De Putte L; Vanhaelst L; Reginster JY;
    Osteoarthritis Cartilage; 2004 Apr; 12(4):263-8. PubMed ID: 15023377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plain radiography or magnetic resonance imaging (MRI): Which is better in assessing outcome in clinical trials of disease-modifying osteoarthritis drugs? Summary of a debate held at the World Congress of Osteoarthritis 2014.
    Eckstein F; Le Graverand MP
    Semin Arthritis Rheum; 2015 Dec; 45(3):251-6. PubMed ID: 26142321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does statin use have a disease modifying effect in symptomatic knee osteoarthritis? Study protocol for a randomised controlled trial.
    Wang Y; Tonkin A; Jones G; Hill C; Ding C; Wluka AE; Forbes A; Cicuttini FM
    Trials; 2015 Dec; 16():584. PubMed ID: 26700937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of osteoarthritis and rheumatoid arthritis: prospects and possibilities.
    Blackburn WD
    Am J Med; 1996 Feb; 100(2A):24S-30S. PubMed ID: 8604723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lorecivivint, an intra-articular potential disease-modifying osteoarthritis drug.
    Sabha M; Siaton BC; Hochberg MC
    Expert Opin Investig Drugs; 2020 Dec; 29(12):1339-1346. PubMed ID: 33096010
    [No Abstract]   [Full Text] [Related]  

  • 18. Emerging pathways and promising agents with possible disease modifying effect in osteoarthritis treatment.
    Jotanovic Z; Mihelic R; Sestan B; Dembic Z
    Curr Drug Targets; 2014 Jun; 15(6):635-61. PubMed ID: 24597569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of interleukin-1 inhibitors in osteoarthritis: an evidence-based review.
    Jotanovic Z; Mihelic R; Sestan B; Dembic Z
    Drugs Aging; 2012 May; 29(5):343-58. PubMed ID: 22550965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What about strontium ranelate in osteoarthritis? Doubts and securities.
    Tenti S; Cheleschi S; Guidelli GM; Galeazzi M; Fioravanti A
    Mod Rheumatol; 2014 Nov; 24(6):881-4. PubMed ID: 24645726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.